Search Results

Pulmonx Announces Treatment of the First Patient with the AeriSeal ® System in CONVERT II Pivotal Trial.

Pulmonx Corporation, a global leader in minimally invasive treatments for lung disease, announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023.

Pulmonx Corporation announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr ® Endobronchial Valve for treating severe COPD/emphysema patients.

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022.

Pulmonx Corporation a global leader in minimally invasive treatments for severe lung disease, announced the company will be participating in fireside chats at two upcoming investor conferences.

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonx’s Zephyr® Valve, for severe emphysema, a form of COPD. This follows similar coverage decisions by other BCBS plans and brings the total BCBS covered members in the US to 59 million.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system